Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit, Jiangsu Wanbang Biopharmaceutical, has had its drug registration application for Metformin hydrochloride and empagliflozin extended release tablets accepted by China's National Medical Products Administration.
Fosun Pharmaceutical has invested approximately 15.3 million yuan in the development of this drug, which is intended to treat type 2 diabetes mellitus, according to a Saturday filing on the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments